Results 231 to 240 of about 205,182 (367)
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara+15 more
wiley +1 more source
The impact of multiple myeloma drugs treatments on autologous stem cell transplantation in the era of new drugs. [PDF]
Wan X, Yu T, Yu T, Cai H.
europepmc +1 more source
The regeneration of LC‐NE from pluripotent stem cells (PSCs) could significantly mitigate the progression of Neurodegenerative diseases and alleviate associated psychiatric disease symptoms, providing a new approach to the treatment of neurological diseases.
Yana Yang, Yunlong Tao
wiley +1 more source
Allogeneic versus autologous stem cell transplantation after relapsing following first line autologous transplantation for multiple myeloma: A systematic review. [PDF]
Ludwig H+11 more
europepmc +1 more source
Advances in the Study of Pluripotent Stem Cells in Livestock
Livestock pluripotent stem cells include embryonic stem cells (ESCs) isolated from the inner cell mass of blastocysts and induced pluripotent stem cells (iPSCs) derived from somatic cell reprogramming. They hold significant potential for applications in livestock breed improvement, rapid propagation, human disease modelling and human organ ...
Xinyi Zhou+6 more
wiley +1 more source
Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report. [PDF]
Castonguay M+18 more
europepmc +1 more source
High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma [PDF]
Scott A. Mink, Jamés O. Armitage
openalex +1 more source